SOURCE: The Bedford Report

The Bedford Report

August 11, 2011 08:16 ET

NeoStem and Cord Blood America Look to Make Splash in Stem Cell Market

The Bedford Report Provides Equity Research on NeoStem and Cord Blood America

NEW YORK, NY--(Marketwire - Aug 11, 2011) - With Americans spending in excess of $300 billion annually on drugs which typically only treat disease symptoms, regenerative therapies are garnering increased support. Scientists argue that stem cells are the future of healthcare, and that regenerative medicine is one of the most misunderstood fields in biotechnology. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides investment research on NeoStem, Inc. (NYSE Amex: NBS) and Cord Blood America, Inc. (OTCBB: CBAI). Access to the full company reports can be found at:

Embryonic stems cell research suffers on-again, off-again bans on US federal funding. Since Obama took office, funding has been less sporadic. Earlier this spring a US appeals court ruled that the Obama administration can continue using federal tax dollars to fund human embryonic stem cell research.

Headlines regarding the funding (or lack thereof) for embryonic stem cell research have a habit of moving all stem cell related stocks, even those not involved in the controversial sector. Very few publicly traded companies are actually engaged in embryonic stem cell research.

The Bedford Report releases stock research on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at and get exclusive access to our numerous analyst reports and industry newsletters.

Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Earlier this summer the company acquired the assets of NeoCells, a subsidiary of ViviCells International, Inc., Evanston, Illinois, through a foreclosure procedure at a purchase price of $320,000.

NeoStem also holds the worldwide exclusive license to VSEL Technology, which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use.

The Bedford Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at

Contact Information